Autopsy report · NCT03325868

Effect of Ulipristal Acetate on Bleeding Patterns and Dysmenorrhea in Women With Adenomyosis

“IND issues”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Vanderbilt University Medical Center

Sponsor type

University, hospital or other

Conditions

Adenomyosis; Heavy Uterine Bleeding; Dysmenorrhea

Interventions

Ulipristal Acetate

Participants

0

Sites

1

Countries

United States

Trials that died the same way

• Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
  “IND withdrawn” (63% match in meaning)
• Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency
  “IND has been closed.” (63% match in meaning)
• The CBD-IC Randomized Controlled Trial: Evaluation of Hemp Cannabidiol SuppositoRies for Pain and Urinary SymptOms in INterstitial Cystitis (CHRONIC)
  “Need to obtain IND approval.” (57% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.